Staar Surg Stock Price, News & Analysis

STAAR Surgical Company (NASDAQ: STAA) announced record financial results for Q1 2022, with net sales reaching $63.2 million, a 25% increase year-over-year. ICL sales accounted for $58.7 million of this total, marking a 26% growth. The company reported a gross margin of 77.9% and net income of $9.6 million ($0.19 per share), up from $5.0 million ($0.10 per share) a year earlier. STAAR also highlighted strong global growth, particularly in China, Japan, and India, and reaffirmed its annual sales outlook of approximately $295 million, a 28% increase from the previous year.

STAAR Surgical Company (NASDAQ: STAA) will announce its financial results for Q1 ending April 1, 2022, on May 4, 2022, post-market close. A conference call is scheduled for the same day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the results. Participants can join by dialing 844-200-6205 (domestic) or 929-526-1599 (international). A replay of the call will be available for seven days after the event. STAAR specializes in implantable lenses and has successfully implanted over 1,000,000 Visian ICLs across more than 75 countries.

STAAR Surgical Company (NASDAQ: STAA) announces the first implants of the EVO Visian® Implantable Collamer® lens (EVO ICL) in the U.S. following product approval. Procedures are set to occur in states including California, Colorado, Missouri, Texas, and Utah. The company also shared its agenda for the ASCRS Annual Meeting in Washington, D.C., from April 22-26, featuring educational events and clinical sessions. President Caren Mason emphasized the U.S. market's significance, representing over 20% of global refractive procedures, and highlighted the excitement around the EVO ICL presentations.

STAAR Surgical has received FDA approval for its EVO/EVO+ Visian® Implantable Collamer® Lens, aimed at correcting myopia and myopia with astigmatism. This innovative lens addresses the growing myopia epidemic, with 100 million U.S. adults aged 21-45 as potential candidates. Over one million EVO lenses have been implanted globally, achieving a 99.4% patient satisfaction rate. With commercialization commencing immediately, this marks a significant step for STAAR in expanding its market presence and addressing the needs of patients seeking alternatives to glasses and contacts.

STAAR Surgical Company (NASDAQ: STAA) reported a strong performance for Q4 and FY 2021, with net sales reaching $59 million for Q4, a 28% increase year-over-year, and full-year sales at $230.5 million, up 41%. Key drivers included a 33% rise in ICL sales and a gross margin increase to 76.3%. Despite challenges due to Covid-19, demand remains robust, especially in China. Net income for Q4 was $4.9 million, or $0.10 per diluted share, compared to $3.3 million a year prior. STAAR projects approximately $295 million in net sales for FY 2022, anticipating another record year.

STAAR Surgical Company (NASDAQ: STAA) will release its financial results for the fourth quarter and fiscal year ending December 31, 2021, on February 23, 2022, post-market. A conference call is scheduled for the same day at 4:30 p.m. ET to discuss these results and operational progress. Participants can join via phone or webcast from the investor relations section on their website. As a leader in ophthalmic surgery for over 30 years, STAAR specializes in implantable lenses designed to enhance visual freedom, with over 1 million Visian ICLs implanted worldwide.

STAAR Surgical reported preliminary results for fiscal year 2021, revealing a strong 40% year-over-year growth with total net sales of approximately $230 million.

The fourth quarter net sales reached about $59 million, and GAAP earnings per share is projected at $0.10 for Q4 and $0.50 for the full year. Despite growth, the company faced challenges due to COVID-related absences and production delays, leading to a backlog of over 20,000 lenses. Looking ahead, STAAR anticipates 2022 net sales of $295 million, assuming no further COVID impact.

STAAR Surgical Company (NASDAQ: STAA) reported strong third quarter results with net sales of $58.4 million, a 24% increase year-over-year. ICL sales reached $54.2 million, up 31%, while unit growth was 29%. Gross margin improved to 77.6%. The company raised its full-year sales outlook to $230 million - $231 million, reflecting over 40% growth. However, a backlog of over 20,000 lenses was noted, partially due to COVID-related challenges. Net income per share grew to $0.12 from $0.08 in the prior year. Cash reserves rose to $196.2 million from $152.5 million.

STAAR Surgical Company (NASDAQ: STAA) will announce its third-quarter financial results on November 3, 2021, after market close. A conference call will follow at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the results and operational progress. Participants can join the call at 844-200-6205 (domestic) or 929-526-1599 (international). A taped replay will be available for seven days after the call. STAAR focuses on developing implantable lenses and delivery systems to enhance visual freedom, having successfully implanted over 1,000,000 Visian ICLs worldwide.